Skip to main content
Veritas In Silico Inc. logo

Veritas In Silico Inc. — Investor Relations & Filings

Ticker · 130A ISIN · JP3155340007 T Professional, scientific and technical activities
Open in API
Filings indexed 18 across all filing types
Latest filing 2024-01-31 Capital/Financing Update
Country JP Japan
Listing T 130A

About Veritas In Silico Inc.

https://www.veritasinsilico.com/

Veritas In Silico Inc. is a drug discovery company that specializes in developing therapeutics targeting messenger RNA (mRNA). The company utilizes its proprietary, AI-driven integrated drug discovery platform, ibVIS®, for in silico target identification and high-throughput screening. Its primary focus is on creating innovative small molecule drugs and nucleic acid medicines. Veritas In Silico operates through a collaborative business model, engaging in joint research and development partnerships with pharmaceutical companies to discover and develop novel treatments for various diseases.

Recent filings

Filing Released Lang Actions
訂正有価証券届出書（新規公開時）
Capital/Financing Update Classification · 98% confidence The document text contains Japanese regulatory headers such as "有価証券届出書" (Securities Registration Statement), "提出書類" (Filing Document), and details related to a public offering ("募集") and secondary offering ("売出") of shares, including issue prices, underwriting details ("引受"), and capital structure information. Specifically, it details the book-building process, issue price (1,000 yen), underwriting price (920 yen), and the intended use of proceeds. This structure and content are characteristic of a registration statement filed in connection with a public offering of securities in Japan, which aligns with the purpose of a Capital/Financing Update (CAP) or potentially a registration statement that might be filed alongside a 10-K or similar comprehensive filing, but the primary focus here is the financing event itself. Given the options, the document describes the terms of a capital raising/offering, making 'CAP' (Capital/Financing Update) the most appropriate classification, as it details the mechanics of the share issuance and sale.
2024-01-31 Japanese
訂正有価証券届出書（新規公開時）
Capital/Financing Update Classification · 98% confidence The document text contains Japanese regulatory headers such as "【提出書類】有価証券届出書(2024年１月23日付け訂正届出書の添付インラインXBRL)" (Filing Document: Securities Registration Statement (Inline XBRL attached to the correction filing dated January 23, 2024)). It details the offering (募集) and selling (売出) of shares, including the book-building method (ブックビルディング方式), issue price (発行価格), underwriting details (株式の引受け), and intended use of proceeds (手取金の使途). This structure and content are characteristic of a registration statement filed in connection with a public offering or sale of securities, which aligns with the definition of a comprehensive registration document, often associated with an IPO or major capital raise. In the context of the provided codes, a comprehensive registration document detailing a public offering/sale of securities, especially one involving underwriting and detailed pricing mechanisms, is best classified as a filing related to Capital/Financing Update (CAP) or potentially a specific type of registration statement. Given the explicit mention of "有価証券届出書" (Securities Registration Statement) and detailed capital raising mechanics (募集/売出), 'CAP' (Capital/Financing Update) is the most appropriate category among the choices, as it covers fundraising activities. It is not a 10-K (Annual Report), IR (Interim Report), or ER (Earnings Release).
2024-01-23 Japanese
有価証券届出書（新規公開時）
Capital/Financing Update Classification · 98% confidence The document text contains Japanese regulatory headers such as "【提出書類】有価証券届出書" (Filing Document: Securities Registration Statement) and details regarding a public offering ("募集") and secondary offering ("売出") of shares, including amounts, dates (e.g., 2024年１月５日提出日), and underwriting details ("株式の引受け"). This structure and content are characteristic of a prospectus or registration statement filed in Japan for a new stock issuance or offering. In the context of US SEC filings, this is analogous to an S-1 or similar registration statement related to capital raising. Among the provided codes, 'CAP' (Capital/Financing Update) is the most appropriate fit as the document is fundamentally about a public offering of shares (募集/売出) and the intended use of proceeds ("手取金の使途"). While it is a comprehensive filing, it is specifically focused on a capital event, making CAP more precise than a general regulatory filing (RNS) or a standard annual/interim report (10-K/IR).
2024-01-05 Japanese

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.